Tag:

Pfizer

Latest Headlines

Latest Headlines

Recent controversy hasn't hurt brand value for Pfizer, Valeant: report

Pfizer and Valeant both posted brand valuation increases greater than 30% in this year's Brand Finance ranking.

FDA vote sets stage for J&J and Pfizer battle over Remicade's $6.5B in sales

Pfizer's biosimilar of blockbuster Remicade looks to be headed to the U.S. market this year after getting very favorable treatment from an FDA advisory committee. Most importantly, Inflectra was recommended for all indications, a key to the drug maxing out its sales potential, as it goes head-to-head with Johnson & Johnson's Remicade, a drug that brought in more than $6.5 billion in the U.S. last year.

Pending Allergan merger stirs layoff fears among Pfizer scientists

Pfizer's planned $160 billion merger with Allergan has some researchers worried the company will embrace its counterpart's austere approach to R&D and mount major layoffs.

Pfizer and Valeant jump in annual brand analysis, but most other pharmas drop

Newsmaker pharmas Pfizer and Valeant Pharmaceuticals both saw brand valuation increases of more than 30% in this year's Brand Finance ranking.

FDA panel backs Pfizer and Celltrion's Remicade biosimilar over J&J's objections

A group of independent FDA advisers voted in favor of OK'ing Pfizer and Celltrion's take on the blockbuster inflammation treatment Remicade for all of the reference drug's approved indications, unswayed by protests from Johnson & Johnson.

Pfizer builds on early Ibrance lead as Novartis, Lilly rivals inch closer

Pfizer's Ibrance has already been prescribed to more than 20,000 patients, and the company says it has a "very heavy" clinical trial program testing it in multiple types of breast cancer and beyond.

Top exec exits as Pfizer redraws org chart for post-megamerger future

Pfizer is shaking up its corporate structure again as it prepares to merge with Allergan and further lays the groundwork for a potential split in a few years. The structural rejig pushes out Geno Germano, who has been leading Pfizer's global innovative pharma business, and elevates one top Allergan manager, Bill Meury, to the combined company's commercial leadership team.

Pfizer keeps pushing on early hit Ibrance as Novartis, Lilly rivals near market

Pfizer's Ibrance has been steamrolling since it nabbed an early FDA go-ahead last February. And even with competition coming up the pipeline from the company's Big Pharma rivals, Pfizer intends to keep it that way.

Celltrion's take on J&J's Remicade is 'highly similar' to the original, FDA says

FDA staff signaled support for Celltrion's biosimilar of Johnson & Johnson's Remicade in documents released ahead of a key panel vote, a positive development for the South Korean company as it works with Pfizer to tap the U.S. market.

Affinivax nets another $2.5M from Gates Foundation to advance Prevnar competitor

Cambridge, MA-based Affinivax launched in November 2014 with a $4 million Gates Foundation investment and plans to develop a pneumococcal vaccine that it believes could go beyond Prevnar, the best-selling vaccine in the world. Now, the biotech is announcing $2.5 million in follow-on funding from the Gates Foundation, which it will use to advance its lead candidate, CEO Steve Brugger told FierceVaccines.